Hepatoblastoma brain metastasis treated with stereotactic radiosurgery: Illustrative case and literature search Authors: Muhammad Izhar, Ahed H. Kattaa, Yusuke S. Hori, Fred C. Lam, Armine Tayag, Louisa Ustrzynski, Sara C. Emrich, Iris C. Gibbs, David J. Park, Steven D. Chang Published: 2025 ABSTRACT Background: Hepatoblastoma (HB) is the most prevalent pediatric liver malignancy, typically affecting children under 5 years of age. Although advances in multimodal therapy, including surgical resection and chemotherapy, have significantly improved survival rates, distant metastases, particularly to the lungs and the brain, remain a critical prognostic challenge. Brain metastases (BMs) from HB are exceedingly rare, with only a limited number of cases reported in the literature, and the management of these lesions is challenging. Stereotactic radiosurgery (SRS) is an increasingly popular treatment option for BM due to its ability to deliver high doses of radiation to the target volume with minimal exposure to surrounding normal tissues. In this paper, we present a rare case of HB with brain metastasis that was treated with SRS for the 1st time.Case Description: The case was a 4-year-old male with a history of stage IV HB who was diagnosed with a single BM. Post-treatment magnetic resonance images following SRS revealed a reduction in lesion size on 6th-month follow-up imaging and then a stable lesion on further follow-up imaging. The case highlights the potential efficacy of SRS as a treatment option for BM from HB and supports its usage in the management of this complex condition. The progression-free survival was 17 months, and the overall survival was 84 months.Conclusion: SRS may represent a safe and effective treatment modality for HB BM, particularly in patients who are not suitable candidates for surgical resection or systemic therapy. Larger studies with extended follow-up are necessary to more accurately assess the long-term safety, efficacy, and clinical utility of SRS in the management of HB-related BM. INTRODUCTION Hepatoblastoma (HB) is the most common primary malignant hepatic tumor in infancy and childhood,[33,39,44] accounting for 1–2% of pediatric malignancies and an annual incidence of 1.5–5 cases/1 million infants.[31,32] It may have a congenital or familial origin.[39] The associated familial syndromes include Beckwith-Weidemann syndrome, Simpson–Golabi–Behmel syndrome, Sotos syndrome, familial adenomatous polyposis coli, and constitutional trisomy 18.[32] Histologically, HB is classified into wholly epithelial or mixed epithelial and mesenchymal types.[41] The diagnosis of HB typically involves detecting an elevated alpha-fetoprotein (AFP) level and identifying a liver mass through radiographic imaging. Definitive confirmation is achieved through pathological examination of samples obtained through primary liver resection or biopsy.[19,41] Approximately 10% of HB cases, particularly those with the small cell undifferentiated/anaplastic (SCUD) subtype, have been reported to exhibit normal serum AFP levels; however, SCUD is recognized as an unfavorable prognostic factor.[41] While HB frequently metastasizes to the lungs, brain metastases (BMs) are rare, presenting unique diagnostic and therapeutic challenges.[18] While the overall prognosis remains poor with BM, long-term survival may be achievable with aggressive multimodal treatment.[16] SRS has been used as a non-invasive treatment option for BM.[9,20] CyberKnife (CK) SRS is a form of radiation therapy that delivers a high radiation dose to the target while sparing surrounding normal tissues.[36] Herein, we present a rare case of HB with BM and, for the 1st time, demonstrate the therapeutic role of CK SRS. ILLUSTRATIVE CASE Case presentation A 4-year-old boy presented with abdominal pain, and subsequent abdominal ultrasound revealed a large, hypervascular hepatic mass. Histopathological examination of a biopsy confirmed HB of the epithelial type, with embryonal and fetal components. The AFP level was elevated at 407,860 ng/ml. Two days later, a computed tomography scan of the abdomen and pelvis showed multiple liver lesions and pulmonary nodules. A staging brain magnetic resonance imaging (MRI) revealed a 7-mm lesion along the cortical surface of the posterior aspect of the left middle frontal gyrus, which appeared hyperintense on T1-weighted and hypointense on T2-weighted sequences. The lesion exhibits susceptibility effects and is surrounded by enhancement [Figure 1], suspicious of BM in the context of known metastatic HB. However, the differential diagnoses could be arteriovenous malformation, arteriovenous fistula, and small aneurysm.[37] He was treated with the SIOPEL-4 protocol, which led to a reduction in the size of the lung and liver lesions but was complicated by electrolyte abnormalities. Despite a decrease in AFP to 1,844 ng/ml, the treatment regimen was switched to ifosfamide, carboplatin, and etoposide (ICE) and later to vincristine, irinotecan, and temozolomide (VIT), with continued response observed on follow-up imaging. Magnetic resonance imaging (MRI) scan of a 4-year-old male patient with brain metastasis secondary to hepatoblastoma, localized in the left middle frontal gyrus. (a) Axial pre-stereotactic radiosurgery treatment MRI. (b) Axial T1-weighted image with contrast enhancement at 6-month follow-up, showing a reduction in the size of the treated lesion. (c) Axial 3D T1-weighted image at 17-month follow-up, demonstrating stable lesion size. No radiation-related side effects were observed during the follow-up period. The white arrows in a/b/c point to the lesion. A brain MRI performed approximately 4 months after diagnosis revealed an unchanged, non-enhancing area of susceptibility in the cortex of the left middle frontal gyrus. The previously noted associated enhancement had resolved. In addition, a stable T2 hyperintense area was observed in the left frontal white matter. A month later, an MRI revealed a small focus of restricted diffusion and gradient echo hypointensity in the left frontal lobe, which appeared slightly reduced in size compared to the prior study and no longer demonstrated enhancement. Our brain tumor board recommended CK SRS for the management of BM to consolidate the effect of systemic therapy. Procedure The CK SRS was planned [Figure 2], and the patient received it 3 weeks later. The CK SRS, using 18 Gy in one fraction, was performed under general anesthesia with intravenous induction and maintenance using propofol (Diprivan). Anesthesia was initiated with a 50 mg bolus, followed by a continuous infusion of 200 mcg/kg/min (17.2 mL/h) throughout the procedure. The airway was managed with a mask and nasal cannula. Immobilization was achieved using a thermoplastic mask, and CK’s real-time motion tracking system was utilized for motion management. The procedure was well tolerated with no anesthetic or procedural complications. The procedure timeline was as below: CyberKnife radiosurgery plan. (a: axial; b: coronal; and c: sagittal). Stereotactic computed tomography and magnetic resonance scans were fused, and standard drawing tools were used to delineate the treatment margins. The lesion was treated with 18 Gy in one fraction, delivering a maximum dose of 25 Gy to the isodose line of 72%. 18 Gy: Green circles; Tumor: Red Component Follow-up At the 3-month follow-up, the MRI showed a decrease in lesion size [Figure 1]. The lesion was locally controlled without any evidence of recurrence until the last brain scan obtained at 17 months following SRS [Figure 1]. The progression-free survival (PFS) after the CK SRS plan was 17 months (calculated from the time of treatment to the time of progression or death/last follow-up imaging, whichever comes first), and the overall survival (OS) after the BM treatment was 84 months. The patient remains alive with a stable brain lesion, no recurrence of BM, and well-controlled systemic disease. DISCUSSION This 4-year-old boy presented to the emergency department with worsening abdominal pain. Subsequent ultrasound imaging and biopsy confirmed a diagnosis of stage IV HB. During follow-up, a brain MRI revealed a lesion with surrounding enhancement. He was treated with chemotherapies (SIOPEL-4, ICE, and VIT) for HB. After systemic therapies, the brain lesion stabilized. He underwent CK SRS (18 Gy) to consolidate the response of systemic therapy, resulting in lesion shrinkage and no recurrence. At 17 months post-treatment, the brain lesion remains stable, with 84 months of OS. The patient is alive with no BM recurrence and well-controlled systemic disease. Metastases from various solid tumors have been known to present as intracranial hemorrhages, sometimes without an identifiable associated mass or contrast enhancement. It is important to note that the absence of contrast enhancement should not exclude the possibility of intracranial metastases in such cases.[2] In our case, the metastatic lesion manifested as an intracranial hemorrhage in a patient with HB. In the literature, most of the patients with BM from HB presented with neurological symptoms, but in our case, the metastasis was small, and the patient was asymptomatic at the time of the diagnosis. SRS delivers high-dose radiation with precision to carefully selected targets and is widely used as a first-line treatment for BM in adults.[7,35] The 1-year OS rates range from 37% to 71.3% for solitary BM in adults.[6,13,14,28,40] It has also been employed in pediatric patients with primary brain tumors.[4,22] A recent study reported the safety and efficacy of CK SRS for pediatric central nervous system (CNS) tumors, suggesting that SRS is a viable option in pediatric brain tumor patients, achieving good local control of recurrent intracranial tumors in pediatric patients while avoiding a head fixation with pinning that is needed in the other types of frame-based SRS.[42] However, in centers where only the Gamma Knife (GK) is available, frameless GK SRS may serve as a feasible and effective alternative for the management of carefully selected pediatric BM. The study reported a 2-year cumulative local failure incidence of 12.8% with one case of grade 4 necrosis.[42] However, the distant intracranial failure rate remained high at 25.3%.[42] Moreover, the short-term complications of SRS in pediatric patients include edema,[1,27,43] and radiation necrosis,[11,17,23,27] while the long-term complications include delayed cyst formation,[8,27,30] bleeding during the latency period,[12,23,27,38,46] and endocrine deficiency when treating craniopharyngioma.[21,24,25] Despite these findings, data on the application of SRS for pediatric BM remain limited.[11] HB is the most common malignant primary hepatic tumor in children.[33,39,44] While rare, CNS metastases are not uncommon.[18] Its treatment approaches and survival outcomes for the cases reported in the literature vary, as shown in Table 1. Table 1:Details of case reports of brain metastases from hepatoblastoma. Details of case reports of brain metastases from hepatoblastoma. In previously reported cases, patients who were treated with chemotherapy and/or radiotherapy had a worse prognosis. One patient who underwent three surgeries in combination with chemoradiotherapy for HB BM had a significantly longer survival of 10+ years,[34] while another patient who underwent whole brain radiotherapy (WBRT) had a survival of more than 2 years.[10] In our case, the patient was treated with CK SRS in addition to chemotherapy to consolidate the effects of the chemotherapy. In previously reported cases, chemotherapy alone did not improve the OS of the patients, but in our case, the SRS in consolidation to chemotherapy significantly improved the survivability of the patient. Post-CK SRS MRIs demonstrated a reduction in lesion size and then a stable lesion, which might be due to post-SRS gliosis. The patient remains alive with an OS of more than 7 years. The typical management of pediatric malignant CNS tumors often includes maximally safe resection, with or without adjuvant radiotherapy and chemotherapy. Nevertheless, recurrent brain tumors are typically more aggressive, with recurrence occurring both locally and distantly after initial treatment. Achieving local control is critical, but repeat surgical interventions are associated with a significant risk of complications. Furthermore, the use of WBRT for HB BM is unlikely to improve outcomes, as it is associated with substantial cognitive and neurological side effects without offering survival benefits. SRS can reduce radiation toxicity and enhance the quality of life by delaying or avoiding the need for more toxic interventions, such as WBRT or additional salvage treatments.[42] CONCLUSION SRS may represent a safe and effective treatment modality for HB BM, particularly in patients who are not suitable candidates for surgical resection or systemic therapy. In our case, a 4-year-old male with stage IV HB and a solitary BM demonstrated radiographic response following SRS, with lesion reduction at 6 months and sustained stability thereafter. The patient achieved a PFS of 17 months and an OS of 84 months, highlighting the potential efficacy of SRS in this setting. However, given the single-case nature of our report and the rarity of HB BM, these findings cannot be generalized. Larger studies with extended follow-up are necessary to more accurately assess the long-term safety, efficacy, and clinical utility of SRS in the management of HB-related BM.